Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2021

View Archived Issues

Anelixis begins phase II study of immunomodulation with AT-1501 in islet cell transplant

Selexis and Pandion to advance development of PT-627

Ventyx initiates dosing in phase I study of VTX-958 for autoimmune diseases

CohBar selects CB5138-3 as lead candidate for IPF and other fibrotic diseases

FDA clears initiation of phase I study of Meissa's COVID-19 vaccine candidate MV-014-212

Therapeutics Solutions plans to use StemVacs to treat COVID-19

T-Cure enters clinical research agreement to support phase I study of KK-LC-1 TCR therapy

Updated interim data reported from phase I/II study of GTB-3550 TriKE

Induced blastocysts are model for earliest development stages

AbbVie presents first-in-human data for ABBV-3373

Immatics reports data updates from ongoing phase I studies of its ACTengine candidates

New results presented for oral formulation of milvexian

Phase III data for omidubicel versus standard UCB in high-risk hematologic malignancies

Chinese phase I study begins with LPM-3480392

Ide-cel induces responses in heavily pretreated patients with refractory/relapsed myeloma

Lipopolysaccharides induce neural repair sweet spot

Data flaws sink current AI models for COVID-19 diagnosis

High blood fats, sugars alter antigen processing

Translate Bio reports second interim analysis of phase I/II trial of MRT-5005 for cystic fibrosis

Phase III topline data reported from ARISE-3 trial of RGN-259 in dry eye

PDE4 inhibitors divulged by Hubei Bio-Pharmaceutical, Humanwell Healthcare

Hefei Institutes of Physical Sciences presents new PDGFR-alpha and/or PDGFR-beta inhibitors

New hydroxyacid oxidase 1 inhibitors discovered at OxaluRx

HBV caspid assembly inhibitors patented by Tibet Tiansheng Taifeng Pharmaceutical

Gilead describes compounds for Filoviridae virus infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...